BRCA2 and metastatic neoplasm: They found that BRCA2 mutation carriers were more likely to be diagnosed with high-risk disease (Gleason 8–10), have advanced clinical stage disease (T3/4), and/or have involvement of local lymph nodes or metastatic disease at diagnosis.